The Real-Time Measurements of Blood Nitric Oxide (NO) and Hydrogen Peroxide (H2O2) Levels under Acute Hyperglycemia by Minni, Michael
Philadelphia College of Osteopathic Medicine
DigitalCommons@PCOM
PCOM Biomedical Studies Student Scholarship Student Dissertations, Theses and Papers
8-2012
The Real-Time Measurements of Blood Nitric
Oxide (NO) and Hydrogen Peroxide (H2O2)
Levels under Acute Hyperglycemia
Michael Minni
Philadelphia College of Osteopathic Medicine, MichaelMin@pcom.edu
Follow this and additional works at: http://digitalcommons.pcom.edu/biomed
Part of the Biochemistry Commons, and the Medicine and Health Sciences Commons
This Thesis is brought to you for free and open access by the Student Dissertations, Theses and Papers at DigitalCommons@PCOM. It has been
accepted for inclusion in PCOM Biomedical Studies Student Scholarship by an authorized administrator of DigitalCommons@PCOM. For more
information, please contact library@pcom.edu.
Recommended Citation
Minni, Michael, "The Real-Time Measurements of Blood Nitric Oxide (NO) and Hydrogen Peroxide (H2O2) Levels under Acute
Hyperglycemia" (2012). PCOM Biomedical Studies Student Scholarship. Paper 38.
                                                                        
 
 
                                                                             
Philadelphia College of Osteopathic Medicine 
The Graduate Program in Biomedical Sciences 
Department of Pathology, Microbiology, Immunology, and Forensic Medicine 
 
 
 
 
 
 
The Real-Time Measurements of Blood Nitric Oxide (NO) and Hydrogen Peroxide 
(H2O2) Levels under Acute Hyperglycemia 
 
 
 
 
A Thesis in Vascular Endothelial Dysfunction by Michael Minni 
 
 
 
 
 
 
 
 
 
Submitted in Partial Fulfillment of the Requirements for the Degree of Masters in 
Biomedical Sciences 
August 2012 
 
 
 
 
 
 
 
© Michael Minni 
 
 
 
 
 
 
 
                                                                        
 
 
                                                                             
This thesis has been presented to and accepted by the Associate Dean for Curriculum and 
Research Office of Philadelphia College of Osteopathic Medicine in partial fulfillment of 
the requirements for the degree of Master of Science in Biomedical Sciences. 
 
 
We the undersigned duly appointed committee have read and examined this manuscript 
and certify it is adequate in scope and quality as a thesis for this master’s degree. We 
approve the content of the thesis to be submitted for processing and acceptance. 
 
 
 
______________________________________ 
 
Qian Chen, Ph.D., Thesis Advisor 
Research Assistant Professor  
Department of Pathology, Microbiology, Immunology, and Forensic Medicine 
 
 
 
_______________________________________ 
 
Farzaneh Daghigh, Ph.D., Thesis Committee Member 
Professor 
Department of Biochemistry and Molecular Biology 
 
 
 
________________________________________ 
 
Christopher Scott Little, Ph.D., Thesis Committee Member 
Associate Professor 
Department of Pathology, Microbiology, Immunology, and Forensic Medicine 
 
 
 
_________________________________________ 
 
Marcus Bell, Ph.D., Program Director, Research Concentration  
Master of Science in Biomedical Sciences 
Associate Professor 
Department of Neuroscience, Physiology, and Pharmacology 
 
iii 
 
                                                                             
 Abstract 
 
Vascular endothelial dysfunction is one of the earliest recognizable events under 
hyperglycemic conditions. It is characterized by decreased endothelium-derived nitric 
oxide (NO) bioavailability and increased oxidative stress, such as superoxide and 
hydrogen peroxide (H2O2) overproduction. However, the real-time changes in blood NO 
and H2O2 levels under acute hyperglycemia have not been evaluated.  In this study, acute 
hyperglycemia (200 mg/dl, 400 mg/dL, and 600 mg/dL) was induced by intravenous 
infusion of 20%, 30%, and 50% D-glucose respectively for 180 min. Infusion of saline or 
30% L-glucose serve as controls.  Blood NO or H2O2 levels were measured at real-time 
by inserting calibrated NO or H2O2 microsensors (100 µm diameter) into each femoral 
vein, respectively. In the saline group, blood NO levels remained stable and only slightly 
decreased by 17.61±8.04 nM (n=7) at 180 min compared to baseline. By contrast, 
hyperglycemia significantly decreased blood NO levels from 100-160 min to the end of 
the experiment.  At 180 min, blood NO levels in 200 mg/dL, 400 mg/dL, and ≥600 
mg/dL groups were 71.3±17.9 nM (n=7), 112.15±15.28 nM (n=6), and 105.98±23.45 nM 
(n=6) lower than that in saline group, respectively (all p<0.01). However, there was no 
significant difference in blood NO levels between L-glucose group and the saline control 
throughout the entire experiment. Blood NO levels were only 11.58±22.01 nM (n=5) 
higher compared to the saline control at 180 min of infusion of 30% L-glucose. 
Meanwhile, blood H2O2 levels in saline group continued to drop and reduced by 
4.62±0.34 µM (n=5) at the end of the 180 min infusion compared to the baseline. By 
contrast, hyperglycemia significantly increased blood H2O2 levels from 20-60 min, then 
stayed higher throughout the rest of the experiment.  At 180 min, blood H2O2 levels in 
200 mg/dL, 400 mg/dL, and 600 mg/dL groups were 2.40±0.61 µM (n=6), 3.1±0.2 µM 
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(n=6), and 2.21±0.37 µM (n=6) higher than that in saline group, respectively (all p<0.01). 
However, blood H2O2 levels in L-glucose group remained similar level as saline control 
throughout the experiment. The blood H2O2 levels were only 0.88±0.29 µM higher in the 
L-glucose group (n=5) compared to the saline control at the end of the experiment. In 
summary, this acute hyperglycemia rat model exhibits vascular endothelial dysfunction 
by presenting significantly lower blood NO levels and significantly higher blood H2O2 
levels, which is not principally due to hyperosmolarity.   
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Introduction 
 
Hyperglycemia and Vascular Complications 
The conditions of hyperglycemia has been emphasized in many diseases, such as 
diabetes, metabolic syndromes, and some post-surgery complications (Fatehi-
Hassanabad, Chan et al.; Ceriello, Hanefeld et al. 2004; Ceriello 2005; Forstermann 
2010). There is considerable evidence indicating that both acute and chronic 
hyperglycemia have deleterious effects on vascular function and are closely related to 
micro and macro vascular complications.  However, the mechanisms underlying 
hyperglycemia-induced vascular and organ damage are complex and unclear.  Therefore, 
it is critical to understand mechanisms involving vascular endothelial dysfunction under 
hyperglycemic conditions for identifying and ultimately developing new treatment 
strategies to attenuate the detrimental effects of hyperglycemia.  
 
1. Clinical Hyperglycemia Conditions 
In normal human subjects, the concentration of fasting whole blood glucose is 
around 101 mg/dL. Hyperglycemia occurs when an individual’s blood glucose level 
exceeds 126 mg/dL. If hyperglycemia persists after at least an 8 hr overnight fast, a 
diagnosis of diabetes is made.  Fasting blood glucose within 110 to 124 mg/dL is 
recognized as impaired fasting glucose (Gardner and Shoback 2007). The oral glucose 
tolerance test is another way to diagnose diabetes. This test requires an individual to 
receive 75 g of glucose solution and then wait for 2 hours, then the blood glucose levels 
will be checked. If an individual’s blood glucose levels exceed 180 mg/dL, then a 
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diagnosis of diabetes is made. Two-hour postprandial blood glucose levels between 121-
178 mg/dL are considered as impaired glucose tolerance. When the blood glucose is 
about 200 mg/dL (i.e. mild hyperglycemia), patients begin to exhibit the symptoms of 
hyperglycemia including excessive thirst, polydipsia, headaches, fatigue and blurred 
vision (Forstermann and Munzel 2006; Gardner and Shoback 2007; Forstermann 2010). 
Ketoacidosis is a complication of diabetes that occurs when the body cannot use glucose 
as a fuel source due to insufficient amount of insulin in the body, and fat is utilized 
instead. This affects individuals with a blood sugar level above 600 mg/dL. This severe 
hyperglycemia can cause weakness and may progress to coma or even death. When blood 
glucose is 700 mg/dL or higher, it can induce hyperglycemic hyperosmolar syndrome 
with more viscous blood due to the excess glucose in the blood and may result in brain 
damage (Ceriello 2005).  
 
2. Acute Hyperglycemia in Non-Diabetic Subjects 
 In non-diabetic subjects, blood glucose levels may increase under some 
conditions such as after a high glucose diet (i.e., oral glucose test), stress, post-surgery, 
medicine, and critical illness (Finney, Zekveld et al. 2003; Falciglia, Freyberg et al. 2009; 
Sato, Carvalho et al. 2010).  Clinically, fasting plasma glucose and postprandial (2 hours 
after meal) glucose levels or oral glucose tolerance test often have been used to indicate 
the acute hyperglycemia level. 
 Both critical illness and postoperative status are accompanied with so-called 
stress-induced hyperglycemia.  It is a transient hyperglycemia during illness rather than 
from previous diabetes mellitus (Dungan, Braithwaite et al. 2009).  Evidence indicates 
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that stress-induced hyperglycemia in critically ill and preoperative patients serves as an 
independent marker of poor outcomes, such as infection, slow recovery, and higher 
mortality (Finney, Zekveld et al. 2003; Falciglia, Freyberg et al. 2009; Sato, Carvalho et 
al. 2010).  If hyperglycemia is left uncontrolled, it can lead to hypokalaemia, 
hypoatraemia, arrhythmias and an increased risk of ischemic brain injury (Hogue, 2006). 
Also hyperglycemia may predispose patients to an increased risk of post-surgical 
infections through impaired phagocytic activity and decreased neutrophil function 
(Rassias, Marrin et al. 1999; Hanazaki, Maeda et al. 2009). Due to the possible danger 
caused from hyperglycemia, it is important to make sure that patients maintain a normal 
blood glucose at all times. Published evidence suggests blood glucose less than 
110mg/dL in critically ill, surgical and non-surgical patients, reduces morbidity and 
mortality (van den Berghe, Wouters et al. 2001).  
Some studies have linked the role of acute hyperglycemia to the development of 
vascular complications in non-diabetic individuals (Forstermann and Munzel 2006). It 
suggests that even in the absence of clinically diagnosed diabetes, high dietary glucose 
consumption and postprandial hyperglycemia are associated with an increased risk of 
cardiovascular disease (Ceriello, Hanefeld et al. 2004). Hanefeld et al. have linked 
postprandial hyperglycemia levels in nondiabetic patients with the incidence of 
mediointimal carotid thickening. In a study containing 403 participants, Hanefeld noted a 
correlation between significant intima-media thickness in the carotid arteries of non 
diabetic individuals and within the 2 hour postprandial glucose spiking (Hanefeld, 
Koehler et al. 1999).  Further evidence suggest that postprandial glucose levels are 
associated with increased production and disturbed removal of triglyceride-rich 
lipoporteins, impaired fibrinolysis and oxidative stress. Hanefeld et al. suggested that 
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postprandial hyperglycemia with oxidative stress may have damaging effects on the 
arterial wall and could accelerate atherosclerosis. It also has been suggested that most 
cardiovascular risk factors may be modified in the postprandial phase and are directly 
affected by an acute increase in blood glucose. One of the primary mechanisms is that 
acute hyperglycemia may cause the overproduction of free radicals, which favors the 
development of vascular endothelial dysfunction (Ding, Aljofan et al. 2007).  
 
3. Chronic Hyperglycemia/Diabetes 
Diabetes mellitus is one of the most common chronic diseases worldwide and is 
associated with both increased morbidity and mortality. It is also characterized by chronic 
hyperglycemia resulting from defects in insulin sensitivity and/or secretion associated 
with different vascular complications (ADA, Diabetes Care 2007). Currently, there are 
about 285 million individuals with diabetes worldwide and by the year 2030, this 
prevalence is expected to increase up to 439 million globally (Wild, Roglic et al. 2004).  
Long term prognosis of individuals with diabetes remains poor because of the 
microvascular and macrovascular complications resulting from chronic hyperglycemia.  
 Diabetic microvascular complications include retinopathy, nephropathy, and 
neuropathy.  In 2009, the American Diabetes Association published data showing 
diabetes is the leading cause of new cases of blindness and kidney failure among adults 
aged 20–74 years.  Moreover, about 60% to 70% of people with diabetes have mild to 
severe forms of nervous system damage. Furthermore, greater than 60% of nontraumatic 
lower-limb amputations occur in people with diabetes (ADA, 2009). In regard to 
macrovascular complications, diabetes is characterized by high incidence of 
cardiovascular diseases (Ceriello 2005). Type II diabetics are two to four times more 
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likely to develop cardiovascular diseases than non diabetic individuals. Sixty-five percent 
of patients with type II diabetes die from complications related to heart disease or stroke 
(Rodriguez, Lau et al. 1999; Milicevic, Raz et al. 2008). 
Postprandial hyperglycemia can play a key role in the pathogenesis of vascular 
complications in diabetes. The clinical follow up study conducted by Meigs revealed that 
fasting hyperglycemia and 2-h post-challenge hyperglycemia independently increase the 
risk for cardiovascular disease, such as heart disease and stroke in diabetic patients 
(Meigs, Nathan et al. 2002).  Furthermore, in the Diabetes Epidemiology: Collaborative 
analysis of Diagnostic criteria in Europe (DECODE) study, mortality risk of 
cardiovascular disease increased with post-glucose load plasma glucose concentrations 
regardless of fasting plasma glucose levels (DECODE Study Group 2001). Postprandial 
hyperglycemia in type II diabetic patients has also been associated with myocardial 
perfusion defects, due to the deterioration in heart microvascular function (Scognamiglio, 
Negut et al. 2006).  Similarly, other studies with type I diabetes patients demonstrated 
that acute hyperglycemia altered myocardial repolarization and increased the stiffness of 
intermediate-sized arteries (Gordon, 2007). 
 
Hyperglycemia and Vascular Endothelial Dysfunction: 
It is very important to maintain the homeostasis of vascular endothelium at resting 
state for proper tissue/organ blood perfusion. Vascular endothelial can be cultivated by 
various stimuli and is involved in the pathogenesis of different diseases, such as 
ischemia/reperfusion injury, hyperglycemia, diabetes, and infectious diseases (Saha, Xia 
et al. 2006; Pate, Damarla et al. 2010).  Hyperglycemia can disturb the homeostasis of 
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vascular endothelium, induce vascular endothelial dysfunction, and initiate the cascade of 
vascular-organ dysfunction.  
 
1. Normal Vascular Endothelial Function 
The vascular endothelium is composed of a monolayer of endothelial cells.  These 
cells line the vascular system and serve as a semi-permeable barrier separating circulating 
blood from the vessel wall and control the transfer of molecules between intravascular 
and extravascular spaces (Sumpio, Riley et al. 2002). Normally, the vascular endothelium 
stays at resting state and acts as an important regulator of vascular homeostasis (Watson, 
Goon et al. 2008). Endothelial cells can also detect alterations in hemodynamic forces 
and respond by synthesizing or releasing a myriad of vasoactive substances including 
prostacyclin and nitric oxide (Sumpio, Riley et al. 2002; Girn, Ahilathirunayagam et al. 
2007; Khazaei, Moien-Afshari et al. 2008).  Therefore, under normal physiological 
conditions, the vascular endothelium primarily serves to provide an antithrombotic 
surface which facilitates adequate blood flow by regulating thrombosis, thrombolysis, 
leukocyte adherence, platelet adherence, and vascular tone (Sumpio, Riley et al. 2002; 
Girn, Ahilathirunayagam et al. 2007; Scalia 2007). 
 
Nitric Oxide 
Nitric Oxide (NO), a potent vasodilator, and is the most important vasoactive 
substance produced by the vascular endothelium (Davignon and Ganz 2004). It serves as 
a vasodilator to all blood vessels in the body as well as reduces inflammation. Under 
normal physiological conditions, endothelial derived NO is produced by the membrane 
bound enzyme endothelial nitric oxide synthase (eNOS) which oxidizes the amino acid, 
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L-arginine, to form the intermediate NG-hydroxy-L-arginine (Govers and Rabelink 2001). 
The two essential cofactors in this reaction are Nicotinamide-adenine-dinucleotide 
phosphate (NADPH) and tetrahydrobiopterin (BH4) (Vanhoutte 2003; Channon 2004).  
The oxygenase domain of eNOS contains a BH4 prosthetic group. By donating a single 
electron, BH4 activates heme bound O2. This is then recaptured to enable NO release 
(Verhaar, Westerweel et al. 2004). It has been indicated that L-arginine and BH4 are 
critical for stabilizing the dimeration of eNOS structure for electron transfer and NO 
production. Thus, eNOS normally produces NO in the presence of an essential cofactor, 
BH4, by facilitating the reduction of molecular oxygen to L-arginine oxidation and 
generation of L-citrulline. This reaction is referred to as eNOS coupling (See Figure 1) 
(Schmidt and Alp 2007).  
 Figure 1. The role of BH4 in regulating eNOS activity.  Endothelial NOS coupling 
occurs during a normal setting allowing the reaction to produce NO and L-citrulline 
from L-arginine /NADPH/O2. When uncoupled, eNOS will produce SO.  Picture is 
adapted from (Schmidt and Alp 2007).  
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The synthesis and release of NO occur in response to stimuli acting on the 
endothelial cell surface and are dependent on the intracellular calcium level (Kharbanda 
and Deanfield 2001). Acetylcholine and physiological stress, such as blood flow shear 
stress, can stimulate the release of NO (Vanhoutte 2003). This is accomplished by 
increasing the intracellular calcium level and facilitating the production of NO from 
eNOS. NO, a potent and lipophilic gas, is able to permeate cell membranes easily and 
diffuse toward smooth muscle cells and into the vascular lumen (See figure 2) (Watson, 
Goon et al. 2008). 
 
 Figure 2.  NO production and its physiological and pathophysiological effects.  
 
NO exerts its effect in smooth muscle cells by binding to the heme group of the 
enzyme guanylyl cyclase (Al-Sa'doni and Ferro 2000). Activated guanylyl cyclase results 
+SO 
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in an increased production of cyclic 3’5’ guanosine monophosphate (cGMP). cGMP is an 
important second messenger which results in dephosphorylation of myosin light chain 
kinase (MLCK) and the activation of cGMP-dependent protein kinase. GMP-dependent 
kinase phosphorylates K+ channels leading to the membrane hyperpolarization and 
reduction of intracellular Ca2+ ions. These collaborative processes result in the relaxation 
of smooth muscle cells (See figure 2) (Lincoln, Komalavilas et al. 1994; Kharbanda and 
Deanfield 2001).  
In addition to its vasodilatory ability, NO has several effects on the cardiovascular 
system which include quenching superoxide radicals for its removal from the body as 
well as its inhibitory effects on  smooth muscle cell proliferation (Laroia, Ganti et al. 
2003).  NO plays an important role in preventing neutrophil adhesion, aggregation, and 
activation (See figure 2) (Girn, Ahilathirunayagam et al. 2007).  Kubes et al. 
demonstrated that the blockade of NO production by using NG nitro L-arginine methyl 
ester (L-NAME), a non-selective NO synthase inhibitor, resulted in a 15-fold increase in 
leukocyte adherence and significant increase in transmigration of leukocytes in cat 
mesenteric post-capillary venules (Kubes, Suzuki et al. 1991). These transmigrated 
leukocytes can ultimately release SO, myeloperoxidase, elastase and cause cell and tissue 
damage (Lefer, 1996). These results indicate endothelial-derived NO is an important 
endogenous inhibitor of leukocyte-endothelial interactions (Kubes, Suzuki et al. 1991). 
In addition to eNOS, two other isoforms of NOS enzyme exist; and each has 
specific functions. Neuronal NOS (nNOS) is found in the nervous system and skeletal 
muscle.  NO release from nNOS is used for transmission from one neuron to another 
while inducible NOS (iNOS) is found in the immune system and utilized by 
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macrophages, neutrophils, and other inflammatory cells (Forstermann and Munzel 2006; 
Keklikoglu 2008).  Neuronal NOS and eNOS are constitutively expressed and tightly 
regulated by calcium and calmodulin. The both NOS forms produce small amounts of 
NO (i.e., nM range), which has precise actions on adjacent cells. In contrast, iNOS is 
calcium and calmodulin independent and produces high levels of nitric oxide (i.e., µM 
range) in response to inflammatory cytokines (Mungrue, Husain et al. 2002). 
A small amount of NO diffuses into smooth muscle, but the majority of the NO 
that does not diffuse abluminally and reacts rapidly with hemoglobin to form nitrate. 
Another fraction of NO produced by eNOS in the vasculature (approximately 20%) 
escapes inactivation by hemoglobin and is oxidized to nitrite (NO2−) in the plasma by 
ceruloplasmin, and functions to modify proteins and lipids to form low concentrations of 
N-nitrosamines, S-nitrosothiols (RSNO), and nitrated lipids. The formation of nitrite may 
serve as stable storage forms of NO that may enzymatically reduced to NO by 
deoxygenated hemoglobin along the physiological oxygen and pH gradient (MacArthur, 
Shiva et al. 2007). 
 
 Reactive Oxygen Species (ROS) 
ROS are molecules derived from oxygen including superoxide (SO), hydrogen 
peroxide, and the hydroxyl radical. They are generated from NADPH oxidase, xanthine 
oxidase, uncoupled eNOS, arachidonic acid metabolizing enzymes (i.e. cytochrome P-
450 enzymes), lipoxygenase and cyclooxygenase, and the mitochondrial respiratory chain 
(Griendling 2005). Normally, they exist at low concentrations and involve physiological 
roles in host defense mechanism (against infectious agents) and in a number of cellular 
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signaling systems (Fatehi-Hassanabad, Chan et al.). Moreover, an intricate balance exists 
between the formation of these oxidizing substances and their removal by antioxidant 
mechanisms under physiological conditions (Girn, Ahilathirunayagam et al. 2007). For 
example, superoxide is a very unstable compound and has a half-life of only a matter of 
seconds. SO is converted to hydrogen peroxide (H2O2) by superoxide dismutase (SOD) 
and subsequently converted to water by catalase to facilitate its removal from the body.  
Thus, the measurement of H2O2 will serve as a good indicator of blood SO production 
(Chen, Kim et al. 2010).   
 
 2. Endothelial Dysfunction and Hyperglycemia 
Vascular endothelium has been considered as an essential component in 
vascular/organ damage because its dysfunction is a common and early feature (Matsuda 
and Hattori 2007; Schafer and Bauersachs 2008). Medical literature mostly defines 
endothelial dysfunction as the impairment of endothelium-dependent vasorelaxation 
caused by the loss of NO bioactivity in vessel walls (Cai and Harrison 2000), and has 
been associated with increased oxidative stress (Sharma and Singh 2001). Clinically, 
noninvasive assessment of endothelial function is to utilize the ultrasound to measure 
blood vessel diameter and blood flow in order to evaluate vasodilators or flow-mediated 
vascular endothelial-dependent vasodilation (Ceriello 2005).  
Hyperglycemia is a cause of vascular endothelial dysfunction by reducing blood 
NO bioavailability (Crabtree, Smith et al. 2008). An abundance of accumulated evidence 
suggests that vascular endothelial dysfunction is one of earliest events induced by 
hyperglycemia.  The oral glucose tolerance test on healthy subjects, which simulates the 
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postprandial hyperglycemia, results in a rapid reduction in endothelial-dependent 
vasodilation at 1 hour and is quickly restored to the normal at 2 hour postchallenge.  
Similarly, the postprandial hyperglycemia in relatively healthy subjects can acutely affect 
endothelium-dependent regulation of blood flow (Triggle 2007). Furthermore, application 
of BH4 to these healthy subjects reverses postprandial hyperglycemia-induced vascular 
endothelial dysfunction at 1 hour (Triggle 2007). By contrast, the recovery of forearm 
vascular endothelial function postchallenge is greatly slowed in diabetic patients who 
have chronic hyperglycemia (Kawano, Motoyama et al. 1999).  
 
 Endothelial NOS and Hyperglycemia 
Endothelial NOS coupling requires the presence of L-arginine and BH4.  
However, when L-arginine is not available or BH4 is oxidized to dihydrobiopterin (BH2) 
which reduces the ratio between BH4 to BH2, eNOS becomes uncoupled and produces 
SO instead of NO by utilizing molecular oxygen (See Figure 1) (Crabtree, Smith et al. 
2008). Although it is suggested that eNOS uncoupling can mediate the vascular 
endothelial dysfunction under hyperglycemia conditions, it is still uncertain that eNOS 
uncoupling is due to the insufficiency of L-arginine or reduced ratio of BH4 to BH2.   
 
Oxidative Stress under hyperglycemia 
Oxidative stress refers the process of cellular damage as a result of the 
uncontrolled action of ROS (Watson, Goon et al. 2008). Oxidative stress occurs in 
response to disruptions in internal homeostasis and disrupts this balance in favor of ROS 
production which overcomes the body’s defense mechanisms (i.e. SOD) (Girn, 
Ahilathirunayagam et al. 2007). The pathologies caused by SO are detrimental and well 
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known (Fan, Sun et al. 2002). SO is known to induce cellular apoptosis and necrosis and 
impairs vasodilatory responses of the vascular endothelium (Fan, Sun et al. 2002). When 
present in high concentrations, superoxide can oxidize lipids (lipid peroxidation), 
proteins, and damage DNA. Under conditions of oxidative stress SO can combine with 
NO. This will inactivate the vasodilatory effects of NO. This process occurs at a rapid 
rate of 6.7 x 109 mol/L-1-s-1 (Thomson, Trujillo et al. 1995).  The new compound 
produced is called peroxynitrite which is very cytotoxic and induces cell damage by 
further uncoupling eNOS dimers to further produce more SO (See Figure 1).  Thereafter, 
endothelial dysfunction can be induced and also serves as a feedback inhibition of NO 
production. (Girn, Ahilathirunayagam et al. 2007).   
When endothelial cells are exposed to high glucose, SO release significantly 
increases (Oak and Cai 2007; Forstermann 2010).  Furthermore, many studies show that 
there exists systemic oxidative stress and lipid oxidation under acute and chronic 
hyperglycemic conditions (McNulty, Tulli et al. 2007). In addition to uncoupled eNOS, 
another important source of SO production in vascular tissue is though the enzyme 
NADPH oxidase. This enzyme is activated by high glucose via a PKC- beta dependent 
process. The use of PKC-beta inhibitors have been shown to prevent hyperglycemia 
induced endothelium dysfunction (Beckman, Goldfine et al. 2002). Additionally, 
xanthine oxidase, NADPH oxidase of neutrophils, and mitochondrial dysfunction also are 
sources for the production of SO. Therefore, anti-oxidants, such as vitamin C helps 
preserve the vascular endothelial function under hyperglycemia conditions (Beckman, 
Goldfine et al. 2001). 
Vascular endothelial dysfunction can further initiate leukocyte-endothelial 
interactions.  Vascular endothelial adhesion molecules such as P-selectin and intercellular 
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adhesion molecule-1(ICAM-1) are upregulated to promote leukocyte rolling, adherence 
and transmigration. Furthermore, transmigrated leukocytes cause inflammatory reactions 
by releasing proteases, SO, and cytokines such as tumor necrosis factor-α.  This 
inflammation can induce organ damage (Piwkowska, Rogacka et al.; Ceriello, Falleti et 
al. 1998). 
 
Hypothesis 
It is accepted that chronic hyperglycemia induces oxidative stress and reduces 
endothelial-derived NO bioavailability, which are closely related to microvascular and 
macrovascular complications of diabetes.  There is increasing evidence suggesting that 
acute hyperglycemia, especially postprandial hyperglycemia, may increase oxidative 
stress and cause vascular endothelial dysfunction in normal subjects (Inoguchi, Battan et 
al. 1992; Ceriello, Hanefeld et al. 2004).  However, it is still uncertain how quickly the 
acute hyperglycemia can impair vascular endothelium dependent vasodilation in healthy 
individuals. Some studies demonstrated that hyperglycemia from one to six hours reduces 
endothelium dependent forearm circulation of healthy subjects (Williams, Goldfine et al. 
1998; Title, Cummings et al. 2000; Beckman, Goldfine et al. 2001). By contrast, 
according to McNulty, a single episode of acute hyperglycemia for one hour causes 
systemic oxidative stress but does not affect endothelium-dependent vasodilation on 
coronary circulation (McNulty, Tulli et al. 2007).  In these studies, they use acetylcholine 
or other vasodilators to evaluate vascular dilatory function but do not directly measure 
blood NO change in real-time. 
15 
 
                                                                             
In order to further understand the influence of hyperglycemia on vascular function 
of a normal subject, it is critical to monitor blood NO and oxidative stress (i.e. H2O2) in 
real-time under hyperglycemic conditions.  Our lab has established a novel method for 
the real-time measurement of blood NO and H2O2 from rat femoral veins (Teng, Kay et 
al. 2008; Chen, Kim et al. 2010). This study aims to establish an acute hyperglycemic 
animal model to evaluate the change of blood NO and H2O2 concentrations in real time.  
 We hypothesize that in the saline control, NO release may be slightly reduced 
due to the decreased body temperature. There will be a decrease in H2O2 release. In 
contrast, hyperglycemia will induce greater decrease in NO compared to saline control. 
Furthermore, H2O2 release will remain at a higher level in the hyperglycemic group as 
opposed to the saline group.  
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Methods 
 
 NO or H2O2 Microsensor Calibration 
 
  Before performing the animal preparation, the NO or H2O2 microsensors (100 µm, 
World Precision Instruments (WPI), Sarasota, FL) were calibrated as per manufacturer’s 
recommendations. The specificity of the free radical microsensors is dependent on the 
selective membrane covering the sensor.  When NO or H2O2 in the solution or biological 
fluid diffuse through the membrane, it is oxidized and an electrical (oxidation/reduction) 
signal is generated of which amplitude is proportional to the free radical concentration in 
the sample.  Each type of sensor has a selective poise voltage important for obtaining 
reliable data, with high performance Faraday shield incorporated in the sensor to 
minimize environmental noise (Zhang, Ju et al. 2008).   
The sensor is calibrated by constructing a standard curve using known 
concentrations of the free radical of interest, enabling conversion of the electrical signal 
recorded during the experiment to a molar concentration of NO or H2O2.  The NO and 
H2O2 microsensors soaked in 10 mL copper sulfate and 10 mL of PBS respectively to 
retrieve a baseline. Moreover, the microsensors were connected with cables which were 
plugged into the Apollo 4000 free radical analyzer (WPI, Sarasota, FL). For calibrating 
NO microsensor, the standard solution (i.e. 100 µM) was made from 50 mL of distilled 
water, 0.01 g of ethylenediaminetetraaceitic acid (EDTA) and 0.011 g of S-Nitroso-N-
Acetyl-D,L-Penicillamine (SNAP). SNAP is a NO donor and the efficiency is 60% when 
using Cu2+.  When the baseline is stable, known concentrations of SNAP (0-200 nM) 
were added to the copper sulfate to generate the current-NO concentrations curve and 
then calculated the calibration formula. To calibrate the H2O2 sensor, the standard (1 
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mM) H2O2 solution was then added to 10 mL of PBS in a range of 0-2 µM to generate the 
standard curve.  
Animal Preparation 
The Institutional Animal Care and Use Committee of Philadelphia College of 
Osteopathic Medicine approved all animal protocols performed in this study.   
Once free radical sensor calibration is complete, male Sprague-Dawley rats 
ranging from 0.275-0.325 kg were anesthetized with 60 mg/kg pentobarbital sodium 
injections with 1000 unit heparin via intraperitoneal (i.p.). Maintenance anesthesia was 
given 30 mg/kg pentobarbital sodium (i.p.) as needed.   
The animal preparation is shown in illustration figures 3 and 4.  Initially, a PE-50 
polyethylene catheter was inserted into the left carotid artery for monitoring mean 
arteriolar blood pressure throughout the entire experiment (see figure 3). Secondly, the 
jugular vein was catheterized (24 gauge catheter) superiorly to inferiorly in order to 
intravenously infuse different solutions, such as 20%, 30%, 50% D-glucose, 30% L-
glucose, or saline (see figure 3). The 20%, 30%, 50% D-glucose, or 30% L-glucose 
solution was freshly made by dissolving D-glucose or L-glucose into saline. Different 
concentrations of D-glucose solutions were used to induce hyperglycemia at 200 mg/dL, 
400 mg/dL, or 600 mg/dL, respectively. Due to the similar structure and weight as well as 
inability for the body to metabolize L-glucose, the 30% L-glucose served as an ideal 
control group for the 30% D-glucose.  
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Figure 3. The catheterization of the jugular vein and carotid artery.  
Both femoral veins were exposed and catheterized in order to place randomly a 
calibrated NO microsensor or a H2O2 microsensor into each respective femoral vein (see 
figure 4). These microsensors were connected to an Apollo 4000 monitor to measure 
blood NO and H2O2 levels in real-time. After 1 hour stabilization period to record 
baseline readings, saline or glucose solutions was administered at a rate of 0.25 mL/min 
for the first four minutes for loading dose, thereafter the infusion speed was maintained at 
rate from a range of 0.018 mL/min to 0.035 mL/min based on the target glucose level 
throughout the remainder of the experiment. Blood pressure, NO and H2O2 were recorded 
at the baseline and at 20 min intervals for a total of 180 min after intravenous infusion of 
saline, D-glucose or L-glucose. In every group, blood glucose was recorded from 
pricking the tail vein at the beginning and every 40 min through the experiment via 
Ascensia Contour blood meter. Moreover, respiratory rate and urination were observed to 
monitor the anesthesia status of the rats during the experiment. 
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Figure 4. Nitric oxide and hydrogen peroxide microsenors in the femoral veins.  
  
After the experiment, the abdominal aorta and the vena cava were removed and 
stored in 4% paraformaldehyde for future analysis of leukocyte vascular adherence. The 
thoracic aorta was harvested and frozen for future immunohistochemistry or western blot 
analysis of adhesion molecules.  
Furthermore, the current changes in NO or H2O2 release during hyperglycemia (in 
picoamps) were expressed as change relative to initial baseline.  Thereafter, the picoamp 
values were converted to the concentration of NO (nM) or H2O2 (µM) after correction to 
the calibration curve of free radical microsensors. In order to further clarify the influence 
of D-glucose or L-glucose on blood NO and H2O2, data was also expressed as relative 
NO or H2O2 change under these conditions by subtracting the NO or H2O2 values of 
saline control group at each time point.  
 
Experimental Groups 
 There were a total of 5 experimental groups in this study: 
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1.) Saline control group (n=7 for NO and n=5 for H2O2): The animal had the same 
surgery and was monitored the blood NO and H2O2 when saline was intravenously 
infused for 3 hours.  This group was selected to show the animal can go through the 
surgery procedures and maintain stable conditions throughout the whole experiment 
period.  Moreover, the level of blood NO and H2O2 in this group reflected the real-time 
vascular endothelial function and served as control to evaluate the change under 
hyperglycemic or hyperosmolarity conditions.  
2.)  Hyperglycemic group (200 mg/dL, n=7 for NO and n=6 for H2O2): The 
animal was intravenously infused with 20% D-glucose in order to maintain 
hyperglycemic condition at 200 mg/dl for 3 hours.  This group was used to evaluate the 
real-time blood NO and H2O2 change at mild hyperglycemic conditions.  
3.)  Hyperglycemic group (400 mg/dL, n=6 for NO and n=6 for H2O2): The 
animal was intravenously infused with 30% D-glucose in order to maintain 
hyperglycemic condition at 400 mg/dl for 3 hours.  This group was used to evaluate the 
real-time blood NO and H2O2 change at moderate hyperglycemic conditions.  
4.)  Hyperglycemic group (≥600 mg/dL, n=6 for NO and n=6 for H2O2): The 
animal was intravenously infused with 50% D-glucose in order to maintain 
hyperglycemic condition at ≥600 mg/dl for 3 hours.  This group was used to evaluate the 
real-time blood NO and H2O2 change at severe hyperglycemic conditions.  
5.) 30% L-glucose group (n=5 for NO and n=5 for H2O2): L-glucose is the 
enantiomer of D-glucose and cannot be synthesized or metabolized by living organisms 
as a source of energy.  30% L-glucose has the same osmolarity as 30% D-glucose.  
Therefore, this group serves as another control for the 30% D-glucose group to indicate if 
high osmolarity is also involved in the change of blood NO and H2O2 under 
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hyperglycemic conditions induced by D-glucose.    
 
Statistics 
All data in text and figures is represented as mean ± SEM.  When comparing 
more than two groups, the analysis was done by ANOVA using post hoc analysis with 
the Bonfferoni/Dunn test to detect differences among experimental groups within each 
group.  Probability values of <0.05 are considered to be statistically significant. 
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Results 
The rats exhibited the normal vital signs for all groups throughout the 
experimental period.  The blood pressure (BP) ranged from 90-130 mm Hg throughout 
the entire experiment except for the slight increase about 10-15 mmHg in blood pressure 
during the first 5 min of 50% D-glucose infusion. However, after 5 min, the blood 
pressure then subsided and remained stable throughout the experiment. In the 
hyperglycemic and L-glucose groups, the rat started to urinate from 20-40 min after 
glucose infusion to the 180 min of infusion.  
 
Blood glucose levels in experimental groups 
 The blood glucose levels in every experimental group are shown in figure 5. The 
baseline of blood glucose ranged from 79-92 mg/dL and there was not significant among 
the groups. Infusion of saline for 180 min slightly raised blood glucose to 100±7 mg/dL 
at the end of the experiment.  
Blood glucose was increased to 197±34 mg/dL after 20 min infusion of 20% D-
glucose. Thereafter, the blood glucose was maintained around 200 mg/dL, showing 
245±35 mg/dL at 60 min, 279±34 mg/dL at 100 min, 268±38 mg/dL at 140 min, and 
247±25 mg/dL at 180 min of the continuous infusion. In 30% D-glucose infusion group, 
blood glucose was raised to 367±18 mg/dL after 20 min infusion. Thereafter, the blood 
glucose was kept around 400-500 mg/dL with continuous infusion.  Blood glucose was 
363±37 mg/dL at 60 min, 481±50 mg/dL at 100 min, 523±40 mg/dL at 140 min, and 
428±30 mg/dL at 180 min of the continuous infusion. In contrast, the 30% L-glucose 
infusion did not dramatically increase blood glucose levels compared to 30% D-glucose, 
the blood glucose at 180 min was about 129±15 mg/dL. This indicated that the infusion 
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of L-glucose has no effect on changing blood glucose levels because L-glucose cannot be 
metabolized as D-glucose.  The infusion of 50% D-glucose increased blood glucose to 
549±22 mg/dL after 60 min infusion interval.  The hyperglycemic condition was then 
remained at a range of 552 ± 20 mg/dL at 100 min, 600.0 ± 0 mg/dL at 140 min and 564 
±25 mg/dL at 180 min.    
 
Figure 5. The comparison of blood glucose levels among saline, L-glucose 
hyperglycemia infusion groups.  
 
Blood H2O2 levels in experimental groups 
Hyperglycemic conditions had significantly higher blood H2O2 levels compared 
to the saline control and L-glucose groups (Figures 6A and 6B).  Figure 6A illustrates the 
H2O2 change relative to the baseline among different experimental groups. In the saline 
group, the blood H2O2 levels continued to drop and reduced by 4.62±0.34 µM (n=5) at 
the end of the 180 min infusion compared to the baseline. In the 200 mg/dL 
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hyperglycemic group, blood H2O2 levels stayed significantly higher at 60 min and 
remained significantly higher throughout the rest of experiment compared to saline group 
(p<0.05, figure 6A).  Furthermore, the blood H2O2 in the 400 mg/dL hyperglycemic 
groups remained significantly higher at most of the experimental time points (i.e. 20, 60, 
80, 100, 120, 140, 160, and 180 min) compared to saline group (p<0.05, figure 6A). 
Moreover, there was a dose-dependent effect in increasing blood H2O2 levels between 
these two hyperglycemic groups.  At 180 min, blood H2O2 levels dropped by 2.22±0.61 
µM (n=6) for 200 mg/dL group and by 1.53±0.20 µM (n=6) for 400 mg/dL group relative 
to baseline. In contrast, 600 mg/dL hyperglycemic group remained high blood H2O2 
levels in the initial 40 minutes then quickly reduced to the similar H2O2 levels as that in 
200 mg/dL group. There was no statistical significance between the 600 mg/dL and 200 
mg/dL groups.  At 180 min, blood H2O2 levels in 600 mg/dL hyperglycemic group 
dropped by 2.42±0.37 µM (n=6) relative to baseline. It was noted that blood H2O2 levels 
in 400 mg/dL hyperglycemic group ended up the highest out of all the groups. However, 
it was not significantly higher when compared to the other hyperglycemic groups. Blood 
H2O2 levels in L-glucose group were significantly lower compared to 400 mg/dL 
hyperglycemic group at most time intervals except for the 40 min and 140 min intervals 
(p<0.05). Moreover, this change was similar as saline control. At 180 min, blood H2O2 
level in L-glucose group reduced by 3.75±0.29 µM (n=5) relative to baseline. 
Figure 6B shows the time course of H2O2 change in hyperglycemic and L-glucose 
infusion groups relative to saline.  Compared to saline control group, hyperglycemia 
significantly increased blood H2O2 levels at most of time points.  By contrast, blood H2O2 
levels in L-glucose group remained similar level (i.e. no statistical significant time points) 
as saline control throughout the experiment. At 180 min, blood H2O2 levels in 200 
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mg/dL, 400 mg/dL, and 600 mg/dL groups were 2.40±0.61 µM, 3.1±0.2 µM, and 
2.21±0.37 µM higher than that in saline group, respectively (all p<0.05). The blood H2O2 
levels were only 0.88±0.29 µM higher in the L-glucose group compared to the saline 
control at the end of the experiment.  
 
 
  
A  
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Figure 6A & 6B.  The comparison of blood H2O2 levels among saline, 
hyperglycemia, and L-glucose groups relative to baseline (6A) or relative to saline 
group (6B).  Hyperglycemic groups exhibited significantly higher blood H2O2 levels 
compared to saline control and L-glucose group (*p<0.05, **p<0.01 compared to 
saline; #p<0.05, ##p<0.01 compared to L-glucose group). The X axis indicates 
duration of experiment and the Y axis indicates the relative change of blood H2O2 in 
µM.  The number of rats used for each group is indicated next to each labeled group.  
 
Blood NO levels in experimental groups 
Hyperglycemic conditions had significantly lower blood NO levels compared to 
the saline control and L-glucose groups (Figures 7A and 7B).  Figure 7A illustrates the 
blood NO levels relative to baseline among the different experimental groups. In the 
saline group, blood NO levels remained stable and only slightly decreased by 17.61±8.04 
nM (n=7) at 180 min. In the 200 mg/dL hyperglycemic group, blood NO continued to 
drop and remained significantly lower level was noted at 160 min and 180 min of 
infusion compared to saline group (p<0.05, figure 7A).  Furthermore, the blood NO in the 
B  
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400 mg/dL hyperglycemic groups decreased immediately after infusion and remained 
significantly lower at 100 min, 120 min, 140 min, 160 min and 180 min  compared to 
saline group (p<0.05, figure 7A). We observed a dose-dependent effect in reducing blood 
NO levels between the 200 mg/dL and the 400 mg/dL hyperglycemic groups.  At 180 
min, blood NO levels decreased by 88.91±17.90 nM (n=7) for 200 mg/dL group and by 
129.76±15.28 nM (n=6) for 400 mg/dL group relative to baseline. By contrast, 600 
mg/dL hyperglycemic group showed an initial NO increase at 20 min of infusion, then 
rapidly dropped below baseline at 60 min and remained significantly lower from 120 min 
to the end of the experiment compared to the saline control (p<0.05, figure 7A). At 180 
min, blood NO levels in 600 mg/dL hyperglycemic group dropped by 123.59±23.45 nM 
(n=6) relative to baseline, which was similar (i.e. no statistical significance) to the NO 
levels in 400 mg/dL hyperglycemic group.  Blood NO levels in L-glucose group were 
significantly higher compared to 400 mg/dL hyperglycemic group from 80 min to 180 
min of infusion (p<0.05, see Fig 7A), which was similar as saline control in that there 
was not any statistical significance between the L-glucose and the saline control at any 
time point. At 180 min of infusion, blood NO levels in L-glucose group slightly changed 
by 6.03±22.01 nM (n=5) relative to baseline. 
The blood NO levels were also analyzed by calculating the change in blood NO 
levels under hyperglycemia or L-glucose relative to saline control group at each time 
point (see figure 7B).  Hyperglycemia significantly decreased blood NO levels at time 
points 100-160 min.  There was no statistical significant difference between blood NO 
levels in L-glucose group and the saline control throughout the entire experiment. At 180 
min, blood NO levels in 200 mg/dL, 400 mg/dL and 600 mg/dL groups were 71.3±17.9 
nM, 112.15±15.28 nM and 105.98±23.45 nM lower than that in saline group, respectively 
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(p<0.01). By contrast, the blood NO levels were only 11.58±22.01 nM (n=5) higher 
compared to the saline control at 180 min of infusion of 30% L-glucose.  
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Figure 7A & 7B.  The comparison of blood NO levels among saline, hyperglycemia, 
and L-glucose groups relative to baseline (7A) or relative to saline group (7B).  
Hyperglycemic groups exhibited significantly lower blood NO levels compared to 
saline control and L-glucose group (*p<0.05, **p<0.01 compared to saline; #p<0.05, 
##p<0.01 compared to L-glucose group).  The X axis indicates duration of 
experiment (i.e. time in minutes) and the Y axis indicates the concentration of blood 
NO in nM. The number of rats used for each group is indicated next to each labeled 
group.  
 
B  
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Discussion 
 
Summary of Results 
 
 The major findings of this study were: first, intravenous infusion of 20%, 30%, 
and 50% of D-glucose induced 200 mg/dL, 400 mg/dL, and 600 mg/dL hyperglycemia, 
respectively, and the different degree of hyperglycemia conditions was maintained for 
180 min with continuous infusion. Second, under hyperglycemic conditions, blood H2O2 
levels were significantly higher as compared to the saline control group. Third, by 
contrast, blood NO levels were significantly lowered under hyperglycemic conditions 
starting at 100 min through the rest of the hyperglycemic period as compared to the saline 
control group. Finally, 30% L-glucose exhibited significantly lower blood H2O2 and 
higher blood NO levels compared to 30% D-glucose, but no statistical significant 
difference was noted between this group and the saline control.  
 
Acute Hyperglycemic rat model 
 We established a successful acute hyperglycemia induced vascular dysfunction rat 
model by measuring blood NO and H2O2 levels in real-time. The hyperglycemic rat 
model was based on the rat model used by Saha et al. (Saha, Xia et al. 2006),  who 
showed that initial bolus injection of 20% glucose producing the maximum acute increase 
in blood glucose level (about 200 mg/dL). This increase was maintained as long as the 
rats received continuous glucose infusion (Saha, Xia et al. 2006). Therefore, we also used 
the bolus infusion of 1 ml D-glucose or L-glucose solution within 4 min for loading dose.  
Then the infusion rate was reduced by 10 fold to maintain the target blood glucose 
concentration throughout the 180 min experiment.  Our blood glucose measurement 
showed that this infusion method can reach 200 mg/dL, 400 mg/dL or 600 mg/dL 
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hyperglycemic conditions around 20-60 min after D-glucose infusion and stayed 
relatively constant for the rest of experiment.  In contrast, 30% L-glucose infusion did not 
cause high blood glucose which differed from the 30% D-glucose group and showed 
similar blood glucose levels as the saline group.   Animals in all groups had relatively 
stable conditions with respect to the respiratory rate and BP. It was noted that there was 
initial increase of BP about 10-15 mmHg when the rats received the bolus injection of 
50% D-glucose.  This was maybe due to the activation of sympathetic nervous system 
responding to the excessively high concentration of D-glucose (Villafana, Huang et al. 
2004). Under hyperglycemic conditions, rats urinated from 20-40 min to the end of 
infusion. This urination was also observed in L-glucose infused rats. Since 30% L-
glucose had a similarly high osmolarity as 30% D-glucose, this data indicated that 
hyperosmolarity was the major cause of urination in the rats.  
 
Increased Levels of H2O2 under Acute Hyperglycemic Conditions 
 We have demonstrated that H2O2 could serve as an indicator of the amount of SO 
produced under different pathophysiological conditions, such as ischemia-reperfusion 
(I/R) (Chen, Kim et al. 2010). In this study, H2O2 levels had dropped approximately 5µM 
within 180 min in the saline group. This phenomenon was most likely attributed to the 
decreased body temperature when the anesthetized rat was placed on a thermostatic board 
for almost 240 min. This H2O2 drop had also been observed in femoral I/R and lithotripsy 
rat models (Chen, Kim et al. 2010; Chen, Rueter et al. 2011). All hyperglycemic groups 
had a significantly higher blood H2O2 levels compared to saline control. The increased 
oxidative stress immediately occurred from the beginning of the intravenous infusion of 
high concentration D-glucose. Furthermore, the 200 mg/dL and 400 mg/dL 
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hyperglycemia groups demonstrated a dose-dependent effect on increasing blood H2O2 
levels. This data was consistent with findings by Iori et al (Iori, Pagnin et al. 2008). Iori 
showed that the 20 mM glucose incubation induced a higher ROS production than the 10 
mM glucose incubation cultured human endothelial cells.  
Furthermore, we found that the 600 mg/dL hyperglycemia group had the highest 
H2O2 levels observed in only the first 20 min and then dropped off to levels similar H2O2 
levels as 200 mg/dL at the end of the experiment. This may be due to the excessively 
high glucose, which may quickly damage the body system, such as causing cell death and 
inhibiting enzymes activity in the body.  In Iori’s experiment, he also found that the 
endothelial cells exposed to 20mM glucose had about 1.5 fold higher incidence of 
apoptosis as compared to the 10mM glucose group. Additionally, the activity of enzyme 
(i.e., heme oxygenase-1) was also reduced to a greater degree in 20 mM glucose (Iori, 
Pagnin et al. 2008). 
The 30% L-glucose group, which has the same osmolarity as 30% D-glucose, 
exhibited significantly lower blood H2O2 levels compared to 400 mg/dL group which was 
infused with 30% D-glucose. The L-glucose is an isomer of glucose, and cannot be 
synthesized or metabolized by the body. Therefore, 30% L-glucose infusion group served 
as a control to test if hyperosmolarity also played a role in hyperglycemia induced blood 
H2O2 change. Our data suggests that high osmolarity caused by L-glucose infusion does 
not significantly contribute the hyperglycemia-induced oxidative stress.  Similarly, 
Nakahata et al. also found that 20 mM D-glucose, not 20 mM L-glucose, significantly 
increased SO production in cerebral arteries after 60 min incubation (Nakahata, Kinoshita 
et al. 2008). This data supports the rationale that hyperglycemia-induced oxidative stress 
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and endothelial dysfunction are the subsequent events after D-glucose circulates in blood 
vessels and is utilized (Ding H and 2010). 
 
Decreased Levels of Blood NO under Hyperglycemic Conditions 
Blood NO levels in our saline group were relatively stable and only slightly 
dropped (by approximately 17 nM) relative to the baseline within the 180 min infusion 
period. The stability of blood NO in anesthetized rats had been observed in our femoral 
I/R and lithotripsy animal models (Chen, Kim et al. 2010; Chen, Rueter et al. 2011). In 
contrast to saline control, hyperglycemia significantly decreased blood NO levels in a 
dose-dependent manner between 200 mg/dL and 400 mg/dL. The 600 mg/dL 
hyperglycemia had an initial spike increase in NO production, and then quickly decreased 
when hyperglycemic condition was maintained. The initial increase of NO followed the 
BP increase caused by the bolus infusion of 50% D-glucose.  Both events may be due to 
the activation of sympathetic nervous system to increase the secretion of epinephrine and 
norepinephrine, which further enhance BP and insulin secretion (Villafana, Huang et al. 
2004). 
Postprandial hyperglycemia has been highlighted in non-diabetic subjects because 
it can induce vascular endothelial dysfunction (Ceriello, Hanefeld et al. 2004).  Kawano 
et al. found that the post-challenge hyperglycemia after oral glucose tolerance test rapidly 
suppressed endothelium-dependent vasodilation, probably through increased production 
of oxygen-derived free radicals in healthy subjects (Kawano, Motoyama et al. 1999). Our 
data by measuring blood NO levels provides clear evidence showing that acute 
hyperglycemia significantly reduces endothelial-derived NO bioavailability. The blood 
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NO measured during 180 min experimental period is not produced from iNOS because 
the synthesis of iNOS needs longer time than 180 min. 
 It is noted that there exists a negative relationship between H2O2 and NO. This is 
because increased superoxide production can directly quench NO. In our study, 400 
mg/dL exhibited the highest blood H2O2 level associated with the lowest blood NO level. 
Moreover, the time course in significant changes of blood NO and H2O2 were different. 
H2O2 levels in the hyperglycemic groups (i.e., 400 mg/dL) were significantly higher at 20 
min of infusion throughout the rest of 180 min experimental period compared to saline 
control.  By contrast, NO levels in the hyperglycemic groups (i.e., 400 mg/dL) started a 
significant drop from 100 min to 180 min of the experiment compared to saline control.  
This discrepancy suggests that oxidative stress occurs relatively rapidly, then it will 
further reduce endothelial-derived NO levels.  Cai et al. has showed that hyperglycemia 
resulted in a decrease in NO production by an increase in superoxide production which 
further causes BH4 deficiency and eNOS uncoupling (Cai and Harrison 2000). 
 
Mechanisms related to hyperglycemia-induced blood NO and H2O2 changes 
Overview 
 A key factor to hyperglycemia-induced vascular endothelial dysfunction is 
oxidative stress. In this study we measured blood H2O2 levels and found that there existed 
oxidative stress under hyperglycemic conditions. It was suggested that the sources of 
oxidative stress under hyperglycemia include NADPH oxidase, uncoupled eNOS, and the 
mitochondria (Fonseca, Ravi et al.; Brownlee 2001; Forstermann and Munzel 2006).  
Moreover, all three sources were suggested to cumulatively produce excess SO in a state 
of hyperglycemia. Thereafter, SO will directly quench NO to form peroxynitrite and 
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reduce NO bioavailability. SO can also be further converted to H2O2 by SOD. Both 
peroxynitrite and H2O2 can cause eNOS uncoupling.  Uncoupled eNOS will produce SO 
instead of NO to facilitate oxidative stress.  Then, more SO can in turn uncouple more 
eNOS.  This interaction between NO and oxidative stress may cause a vicious and 
detrimental cycle (see figure 8). This detrimental cycle can further cause vascular 
dysfunction, persistent inflammation, and tissue/organ damage. Furthermore, this cycle 
may provide a rationale to explain that H2O2 was significantly increased from the 
beginning of hyperglycemia, whereas NO did not significantly decrease until a later time 
of this experiment.    
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Figure 8.  Model of vicious cycle under hyperglycemic conditions. An overview of 
the mechanism of how the generation of free radicals from hyperglycemia can cause 
a continuous production of more free radicals.  
 
NADPH Oxidase 
 NADPH oxidase is a membrane bound and cytosolic enzyme producing 
superoxide by the utilization of NADPH. In addition to neutrophils, NADPH oxidase also 
presents in endothelial cells, vascular smooth muscle cells, and other cells.  The 
physiological NADPH oxidase derived SO has been implicated in the regulation of 
vascular tone, vascular cell growth, migration, proliferation, and activation (Touyz 2003; 
Cai 2005). However, if NADPH oxidase is upregulated, higher amounts of SO may result 
in oxidative stress.  Numerous studies have indicated that high glucose levels can activate 
the enzyme protein kinase C (PKC) in vascular cells. High glucose might stimulate SO 
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production through PKC-dependant activation of NADPH oxidase in vascular cells 
(Inoguchi, Li et al. 2000). Inogouchi et al. found that exposure of aortic endothelial cells 
to a high glucose level (400 mg/dL) for 72 hrs induced a significant increase in free 
radical production as opposed to cells that were exposed only to a glucose level of 100 
mg/dL (Inoguchi, Li et al. 2000). Inogouchi also found that the increase in free radical 
production was negated through the use of diphenylene iodonium, a NADPH oxidase 
inhibitor (Inoguchi, Li et al. 2000). These results from Inoguchi suggest that high glucose 
levels may stimulate ROS production through the activation of NADPH oxidase. 
Furthermore, it has been found that SO production is significantly increased in 
streptozotocin-induced diabetic rats 2 weeks after the onset of diabetes.  By contrast, 
NADPH oxidase inhibitor or PKC inhibitor can significantly attenuate this oxidative 
stress (Sonta, Inoguchi et al. 2004).  It will be very interesting for us to investigate if a 
NADPH oxidase inhibitor can attenuate the blood H2O2 increase/NO decrease in this 
acute hyperglycemia model in the near future. 
 
Uncoupled eNOS 
 Normally, in the presence of co-factor, BH4, eNOS can keep electron transfer 
coupled with oxidation of L-arginine and then generate NO, which is defined as eNOS 
coupling (Schmidt and Alp 2007). Moreover, BH4 and the amino acid L-arginine can 
stabilize eNOS dimer structure which has catalytic function (Fonseca, Ravi et al.). When 
BH4 is oxidized to BH2, BH2 occupies the eNOS oxygenase domain, and blocks electron 
transfer to L-arginine, eNOS becomes uncoupled and dissociates to become a monomer, 
and then generates SO instead of NO (Vasquez-Vivar, Kalyanaraman et al. 1998). 
Fonseca et al. found that H2O2 can induce a collapse in the eNOS dimer resulting in 
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eNOS uncoupling (Fonseca, Ravi et al.). Additionally, the overproduced SO under 
hyperglycemia can bind NO to form the peroxynitrite.  Peroxynitrite is very potent in 
oxidizing BH4 to BH2 resulting in decreased BH4 to BH2 ratio.  Thereafter, eNOS 
becomes uncoupled and produce SO instead of NO (Crabtree, Smith et al. 2008). Thereby 
it is evident that a vicious cycle of oxidative stress under hyperglycemia can propagate: 
increased SO production directly reduces NO bioavailability by forming peroxynitrite.  
Moreover, peroxynitrite and H2O2 further cause eNOS uncoupling to produce SO instead 
of NO.  Thereafter, more SO is generated, whereas less NO is produced. This process can 
keep repeating and can cause serious damage on vascular endothelial function. Therefore, 
uncoupled eNOS can be another source subsequent to oxidative stress induced by 
hyperglycemia to further exacerbate blood NO and H2O2 changes and vascular 
endothelial dysfunction. This vicious cycle can also help explain the time difference in 
blood NO and H2O2 significant changes found in this hyperglycemic study.    
 
Mitochondrial SO production 
Oxidative phosphorylation to generate ATP is the most prominent function of 
mitochondria. The system of oxidative phosphorylation includes five large multienzyme 
complexes.  In normal physiological conditions and in most tissues, this system is an 
important source of SO.  Meanwhile, SOD inside mitochondria can remove the SO to 
protect the mitochondria. Under hyperglycemia, it is hypothesized that there exists the 
increased hyperglycemia-derived electron donors from the TCA cycle (NADH and 
FADH2), increases the mitochondrial membrane potential. This increased membrane 
potential inhibits electron transport at complex III, increasing the half-life of free-radical 
intermediates of co-enzyme Q, which reduce O2 to SO (Brownlee 2001). This has been 
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proved by Srinivasan et al.  They found that chronic exposure of human aortic endothelial 
cells to elevated glucose (25 mM) reduced total nitrite levels, eNOS mRNA and eNOS 
protein. This effect was reduced by the specific inhibition of reactive oxygen species 
production through the mitochondrial electron transport chain (Srinivasan, Hatley et al. 
2004). These findings demonstrate that another possible source of SO under 
hyperglycemic condition is from the mitochondria.   
 
D-glucose scavenging of NO 
Moreover, in vitro, hyperglycemia can also be another factor in the significant 
decrease of NO.  Brodsky et al. found that glucose can directly quench NO by the direct 
scavenging effect. He also correlated a link of diminished availability of NO in blood 
vessels when they were exposed to glucose. Furthermore, Brodsky provided experimental 
evidence showing that the healthy human subjects had a small, but significant reduction 
in NO-mediated vasoactivity when blood glucose was elevated to 270 mg/dL (Brodsky, 
Morrishow et al. 2001).  This could serve as another possible factor to explain the drop in 
blood NO levels under acute hyperglycemic conditions.  
 
Limitations/Future Studies 
 In this study, the blood NO and H2O2 levels were analyzed relative to the baseline 
or saline group. The free radical microsensor was calibrated before the experiment to test 
the sensitivity. Moreover, the correct poise voltage setup can also warrant the accuracy of 
the microsensors by defining the appropriate range for NO and H2O2 measurements. 
After the experiments, blood was collected and we plan to conduct fluorescence Griess 
Assay to measure the blood nitrite levels to confirm our NO data. Furthermore, blood 
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malondialdehyde concentration is also needed to reflect systemic lipid oxidation due to 
oxidative stress induced by hyperglycemic conditions.   
We did appreciate that there may exist hyperinsulinemia in hyperglycemic rats.  
Our hyperglycemic rat model is induced in normal rats with normal insulin secretion 
responding to blood glucose change.  It has been shown that hyperinsulinemia can cause 
less SO and more NO production.  However, due to the continuation of D-glucose 
infusion, the excessive amount of D-glucose overrides on the effects of insulin to 
maintain hyperglycemic conditions.  Therefore, the blood NO and H2O2 changes 
observed by this study can still indicate the detrimental effects on vascular function by 
hyperglycemia.  
Furthermore, this is a pilot study to establish the acute hyperglycemic rat model 
and measure blood NO and H2O2 changes in real-time. We found that hyperglycemia 
maintained significantly higher H2O2 levels associated with significantly lower blood NO 
levels. It has been suggested that NADPH oxidase and eNOS uncoupling may be the 
important sources for these changes.  Therefore, the further studies are needed to explore 
these related mechanisms by using NADPH oxidase inhibitor (diphenylene iodonium), or 
coupled eNOS cofactor (BH4), or coupled eNOS substrate (L-arginine) with D-glucose 
infusion. 
 
Conclusion  
          In summary, this study established an acute hyperglycemia-induced vascular 
dysfunction rat model by measuring blood NO and H2O2 levels in real-time.  We found 
that acute hyperglycemia had a significantly higher blood H2O2 levels associated with 
significantly lower blood NO levels.  The oxidative stress occurred immediately after 
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induction of hyperglycemia, whereas reduced endothelial-derived NO bioavailability 
took place at the later time points of hyperglycemia.  This study indicates that oxidative 
stress is a predecessor of vascular endothelial dysfunction under hyperglycemic 
conditions and suggests that acute hyperglycemia for 180 min increased oxidative stress 
and reduced endothelial-derived NO bioavailability, which may not be due to high 
osmolarity.  
 
Clinical Relevance  
 As stated in the introduction, hyperglycemia is linked to vascular endothelial 
dysfunction by increasing oxidative stress. Prolonged oxidative stress and vascular 
endothelial dysfunction most likely contribute to cardiovascular disease and 
atherosclerosis. The purpose of this pilot study was to establish a hyperglycemic model to 
test the relevant mechanisms to help prevent vascular dysfunction and other circulatory 
complications in diabetic and non-diabetic individuals. Hyperglycemia has been linked to 
the progression diabetic nephropathy. Hyperglycemia caused a production of reactive 
oxygen species that caused morphological and functional changes in mouse podocytes 
(Piwkowska, Rogacka et al.). It is also important to maintain normal glucose levels 
during surgery to avoid blood clots and stoke as well. Another factor that can cause 
hyperglycemia is psychological stress. To avoid future vascular complications, it is 
important for an individual to eliminate chronic psychological stress.    
This could also bring awareness to the public about the hazards of postprandial 
hyperglycemia. It is a well known that consumption of excess dietary saturated fat and 
dietary sodium is directly linked to heart diseases. To promote better health, some 
individuals place some dietary restrictions on dietary fat and sodium. However, sugars 
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such as those found in soda, candy, etc. are not commonly seen through the eyes of the 
public as hazardous to heart health. It is known that a 20 oz bottle of the leading grape 
soda contains 81 g of sugar. When consuming a 20 oz bottle of this soda, one should 
anticipate similar vascular function changes as to the individuals in the 75 g post oral 
glucose challenge test mentioned in the introduction. This study provides the basic 
evidence for public to raise the awareness of the possible harmful impact of a high sugar 
diet on vascular function.  
43 
 
                                                                             
References 
Al-Sa'doni, H. and A. Ferro (2000). "S-Nitrosothiols: a class of nitric oxide-donor drugs." Clin 
Sci (Lond) 98(5): 507-20. 
Beckman, J. A., A. B. Goldfine, et al. (2001). "Ascorbate restores endothelium-dependent 
vasodilation impaired by acute hyperglycemia in humans." Circulation 103(12): 1618-23. 
Beckman, J. A., A. B. Goldfine, et al. (2002). "Inhibition of protein kinase Cbeta prevents 
impaired endothelium-dependent vasodilation caused by hyperglycemia in humans." Circ 
Res 90(1): 107-11. 
Brodsky, S. V., A. M. Morrishow, et al. (2001). "Glucose scavenging of nitric oxide." Am J 
Physiol Renal Physiol 280(3): F480-6. 
Brownlee, M. (2001). "Biochemistry and molecular cell biology of diabetic complications." 
Nature 414(6865): 813-20. 
Cai, H. (2005). "NAD(P)H oxidase-dependent self-propagation of hydrogen peroxide and 
vascular disease." Circ Res 96(8): 818-22. 
Cai, H. and D. G. Harrison (2000). "Endothelial dysfunction in cardiovascular diseases: the role 
of oxidant stress." Circ Res 87(10): 840-4. 
Ceriello, A. (2005). "Postprandial hyperglycemia and diabetes complications: is it time to treat?" 
Diabetes 54(1): 1-7. 
Ceriello, A., E. Falleti, et al. (1998). "Hyperglycemia-induced circulating ICAM-1 increase in 
diabetes mellitus: the possible role of oxidative stress." Horm Metab Res 30(3): 146-9. 
Ceriello, A., M. Hanefeld, et al. (2004). "Postprandial glucose regulation and diabetic 
complications." Arch Intern Med 164(19): 2090-5. 
Channon, K. M. (2004). "Tetrahydrobiopterin: regulator of endothelial nitric oxide synthase in 
vascular disease." Trends Cardiovasc Med 14(8): 323-7. 
Chen, Q., E. J. Kim, et al. (2010). "The role of Tetrahydrobiopterin (BH4) and Dihydrobiopterin 
(BH2) in ischemia/reperfusion (I/R) injury when given at reperfusion." Advances in 
Phamacological Sciences 2010 Artical ID 963914. 
Chen, Q., B. M. Rueter, et al. (2011). "The potential clinical application of protein kinase C beta 
II peptide inhibitor or Gö 6983 in vascular endothelial dysfunction." Current Topics in 
Pharmacology (in press). 
Crabtree, M. J., C. L. Smith, et al. (2008). "Ratio of 5,6,7,8-tetrahydrobiopterin to 7,8-
dihydrobiopterin in endothelial cells determines glucose-elicited changes in NO vs. 
superoxide production by eNOS." Am J Physiol Heart Circ Physiol 294(4): H1530-40. 
Davignon, J. and P. Ganz (2004). "Role of endothelial dysfunction in atherosclerosis." 
Circulation 109(23 Suppl 1): III27-32. 
DECODE Study Group, t. E. D. E. G. (2001). "Glucose tolerance and cardiovascular mortality: 
comparison of fasting and 2-hour diagnostic criteria." Arch Intern Med 161(3): 397-405. 
Ding, H., M. Aljofan, et al. (2007). "Oxidative stress and increased eNOS and NADPH oxidase 
expression in mouse microvessel endothelial cells." J Cell Physiol 212(3): 682-9. 
Dungan, K. M., S. S. Braithwaite, et al. (2009). "Stress hyperglycaemia." Lancet 373(9677): 
1798-807. 
Falciglia, M., R. W. Freyberg, et al. (2009). "Hyperglycemia-related mortality in critically ill 
patients varies with admission diagnosis." Crit Care Med 37(12): 3001-9. 
Fan, H., B. Sun, et al. (2002). "Oxygen radicals trigger activation of NF-kappaB and AP-1 and 
upregulation of ICAM-1 in reperfused canine heart." Am J Physiol Heart Circ Physiol 
282(5): H1778-86. 
Fatehi-Hassanabad, Z., C. B. Chan, et al. "Reactive oxygen species and endothelial function in 
diabetes." Eur J Pharmacol 636(1-3): 8-17. 
Finney, S. J., C. Zekveld, et al. (2003). "Glucose control and mortality in critically ill patients." 
Jama 290(15): 2041-7. 
44 
 
                                                                             
Fonseca, F. V., K. Ravi, et al. "Mass spectroscopy and molecular modeling predict endothelial 
nitric oxide synthase dimer collapse by hydrogen peroxide through zinc tetrathiolate 
metal-binding site disruption." DNA Cell Biol 29(3): 149-60. 
Forstermann, U. (2010). "Nitric oxide and oxidative stress in vascular disease." Pflugers Arch 
459(6): 923-39. 
Forstermann, U. and T. Munzel (2006). "Endothelial nitric oxide synthase in vascular disease: 
from marvel to menace." Circulation 113(13): 1708-14. 
Gardner, D. G. and D. Shoback (2007). Greenspan's Basic & Clinical Endocrinology, 8e. 
Girn, H. R., S. Ahilathirunayagam, et al. (2007). "Reperfusion syndrome: cellular mechanisms of 
microvascular dysfunction and potential therapeutic strategies." Vasc Endovascular Surg 
41(4): 277-93. 
Govers, R. and T. J. Rabelink (2001). "Cellular regulation of endothelial nitric oxide synthase." 
Am J Physiol Renal Physiol 280(2): F193-206. 
Griendling, K. K. (2005). "ATVB in focus: redox mechanisms in blood vessels." Arterioscler 
Thromb Vasc Biol 25(2): 272-3. 
Hanazaki, K., H. Maeda, et al. (2009). "Relationship between perioperative glycemic control and 
postoperative infections." World J Gastroenterol 15(33): 4122-5. 
Hanefeld, M., C. Koehler, et al. (1999). "Postprandial plasma glucose is an independent risk 
factor for increased carotid intima-media thickness in non-diabetic individuals." 
Atherosclerosis 144(1): 229-35. 
Inoguchi, T., R. Battan, et al. (1992). "Preferential elevation of protein kinase C isoform beta II 
and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to 
glycemic control by islet cell transplantation." Proc Natl Acad Sci U S A 89(22): 11059-
63. 
Inoguchi, T., P. Li, et al. (2000). "High glucose level and free fatty acid stimulate reactive oxygen 
species production through protein kinase C--dependent activation of NAD(P)H oxidase 
in cultured vascular cells." Diabetes 49(11): 1939-45. 
Iori, E., E. Pagnin, et al. (2008). "Heme oxygenase-1 is an important modulator in limiting 
glucose-induced apoptosis in human umbilical vein endothelial cells." Life Sci 82(7-8): 
383-92. 
Kawano, H., T. Motoyama, et al. (1999). "Hyperglycemia rapidly suppresses flow-mediated 
endothelium-dependent vasodilation of brachial artery." J Am Coll Cardiol 34(1): 146-
54. 
Keklikoglu, N. (2008). "Inducible nitric oxide synthase immunoreactivity in healthy rat 
pancreas." Folia Histochem Cytobiol 46(2): 213-7. 
Kharbanda, R. K. and J. E. Deanfield (2001). "Functions of the healthy endothelium." Coron 
Artery Dis 12(6): 485-91. 
Khazaei, M., F. Moien-Afshari, et al. (2008). "Vascular endothelial function in health and 
diseases." Pathophysiology 15(1): 49-67. 
Kubes, P., M. Suzuki, et al. (1991). "Nitric oxide: an endogenous modulator of leukocyte 
adhesion." Proc Natl Acad Sci U S A 88(11): 4651-5. 
Laroia, S. T., A. K. Ganti, et al. (2003). "Endothelium and the lipid metabolism: the current 
understanding." Int J Cardiol 88(1): 1-9. 
Lincoln, T. M., P. Komalavilas, et al. (1994). "Pleiotropic regulation of vascular smooth muscle 
tone by cyclic GMP-dependent protein kinase." Hypertension 23(6 Pt 2): 1141-7. 
MacArthur, P. H., S. Shiva, et al. (2007). "Measurement of circulating nitrite and S-nitrosothiols 
by reductive chemiluminescence." J Chromatogr B Analyt Technol Biomed Life Sci 
851(1-2): 93-105. 
Matsuda, N. and Y. Hattori (2007). "Vascular biology in sepsis: pathophysiological and 
therapeutic significance of vascular dysfunction." J Smooth Muscle Res 43(4): 117-37. 
45 
 
                                                                             
McNulty, P. H., M. A. Tulli, et al. (2007). "Effect of simulated postprandial hyperglycemia on 
coronary blood flow in cardiac transplant recipients." Am J Physiol Heart Circ Physiol 
293(1): H103-8. 
Meigs, J. B., D. M. Nathan, et al. (2002). "Fasting and postchallenge glycemia and cardiovascular 
disease risk: the Framingham Offspring Study." Diabetes Care 25(10): 1845-50. 
Milicevic, Z., I. Raz, et al. (2008). "Natural history of cardiovascular disease in patients with 
diabetes: role of hyperglycemia." Diabetes Care 31 Suppl 2: S155-60. 
Mungrue, I. N., M. Husain, et al. (2002). "The role of NOS in heart failure: lessons from murine 
genetic models." Heart Fail Rev 7(4): 407-22. 
Nakahata, K., H. Kinoshita, et al. (2008). "Propofol restores brain microvascular function 
impaired by high glucose via the decrease in oxidative stress." Anesthesiology 108(2): 
269-75. 
Oak, J. H. and H. Cai (2007). "Attenuation of angiotensin II signaling recouples eNOS and 
inhibits nonendothelial NOX activity in diabetic mice." Diabetes 56(1): 118-26. 
Pate, M., V. Damarla, et al. (2010). "Endothelial cell biology: role in the inflammatory response." 
Adv Clin Chem 52: 109-30. 
Piwkowska, A., D. Rogacka, et al. "High glucose concentration affects the oxidant-antioxidant 
balance in cultured mouse podocytes." J Cell Biochem 112(6): 1661-72. 
Rassias, A. J., C. A. Marrin, et al. (1999). "Insulin infusion improves neutrophil function in 
diabetic cardiac surgery patients 
Psychological factors in nutritional disorders of the elderly: part of the spectrum of eating 
disorders." Anesth Analg 88(5): 1011-6. 
Rodriguez, B. L., N. Lau, et al. (1999). "Glucose intolerance and 23-year risk of coronary heart 
disease and total mortality: the Honolulu Heart Program." Diabetes Care 22(8): 1262-5. 
Saha, J. K., J. Xia, et al. (2006). "A model of controlled acute hyperglycemia in rats: Effects of 
insulin and glucagon-like peptide-1 analog." J Pharmacol Exp Ther 316(3): 1159-64. 
Sato, H., G. Carvalho, et al. (2010). "The association of preoperative glycemic control, 
intraoperative insulin sensitivity, and outcomes after cardiac surgery." J Clin Endocrinol 
Metab 95(9): 4338-44. 
Scalia, R. (2007). "Evaluation of endothelial function by in vivo microscopy." Methods Mol Med 
139: 225-36. 
Schafer, A. and J. Bauersachs (2008). "Endothelial dysfunction, impaired endogenous platelet 
inhibition and platelet activation in diabetes and atherosclerosis." Curr Vasc Pharmacol 
6(1): 52-60. 
Schmidt, T. S. and N. J. Alp (2007). "Mechanisms for the role of tetrahydrobiopterin in 
endothelial function and vascular disease." Clin Sci (Lond) 113(2): 47-63. 
Scognamiglio, R., C. Negut, et al. (2006). "Detection of coronary artery disease in asymptomatic 
patients with type 2 diabetes mellitus." J Am Coll Cardiol 47(1): 65-71. 
Sharma, A. and M. Singh (2001). "Protein kinase C activation and cardioprotective effect of 
preconditioning with oxidative stress in isolated rat heart." Mol Cell Biochem 219(1-2): 
1-6. 
Sonta, T., T. Inoguchi, et al. (2004). "Evalution of oxidative stress in diabetic animals by in vivo 
electron spin resonance measurement--role of protein kinase C." Diabetes Res Clin Pract 
66 Suppl 1: S109-13. 
Srinivasan, S., M. E. Hatley, et al. (2004). "Hyperglycaemia-induced superoxide production 
decreases eNOS expression via AP-1 activation in aortic endothelial cells." Diabetologia 
47(10): 1727-34. 
Sumpio, B. E., J. T. Riley, et al. (2002). "Cells in focus: endothelial cell." Int J Biochem Cell Biol 
34(12): 1508-12. 
46 
 
                                                                             
Teng, J. C., H. Kay, et al. (2008). "Mechanisms related to the cardioprotective effects of protein 
kinase C epsilon (PKC epsilon) peptide activator or inhibitor in rat ischemia/reperfusion 
injury." Naunyn Schmiedebergs Arch Pharmacol 378(1): 1-15. 
Thomson, L., M. Trujillo, et al. (1995). "Kinetics of cytochrome c2+ oxidation by peroxynitrite: 
implications for superoxide measurements in nitric oxide-producing biological systems." 
Arch Biochem Biophys 319(2): 491-7. 
Title, L. M., P. M. Cummings, et al. (2000). "Oral glucose loading acutely attenuates 
endothelium-dependent vasodilation in healthy adults without diabetes: an effect 
prevented by vitamins C and E." J Am Coll Cardiol 36(7): 2185-91. 
Touyz, R. M. (2003). "Reactive oxygen species in vascular biology: role in arterial hypertension." 
Expert Rev Cardiovasc Ther 1(1): 91-106. 
Triggle, C. R. (2007). "The early effects of elevated glucose on endothelial function as a target in 
the treatment of type 2 diabetes." Drugs Today (Barc) 43(11): 815-26. 
van den Berghe, G., P. Wouters, et al. (2001). "Intensive insulin therapy in the critically ill 
patients." N Engl J Med 345(19): 1359-67. 
Vanhoutte, P. M. (2003). "Endothelial control of vasomotor function: from health to coronary 
disease." Circ J 67(7): 572-5. 
Vasquez-Vivar, J., B. Kalyanaraman, et al. (1998). "Superoxide generation by endothelial nitric 
oxide synthase: the influence of cofactors." Proc Natl Acad Sci U S A 95(16): 9220-5. 
Verhaar, M. C., P. E. Westerweel, et al. (2004). "Free radical production by dysfunctional 
eNOS." Heart 90(5): 494-5. 
Villafana, S., F. Huang, et al. (2004). "Role of the sympathetic and renin angiotensin systems in 
the glucose-induced increase of blood pressure in rats." Eur J Pharmacol 506(2): 143-50. 
Watson, T., P. K. Goon, et al. (2008). "Endothelial progenitor cells, endothelial dysfunction, 
inflammation, and oxidative stress in hypertension." Antioxid Redox Signal 10(6): 1079-
88. 
Wild, S., G. Roglic, et al. (2004). "Global prevalence of diabetes: estimates for the year 2000 and 
projections for 2030." Diabetes Care 27(5): 1047-53. 
Williams, S. B., A. B. Goldfine, et al. (1998). "Acute hyperglycemia attenuates endothelium-
dependent vasodilation in humans in vivo." Circulation 97(17): 1695-701. 
Zhang, X., H. Ju, et al. (2008). "Electro-chemical sensors, biosensors and their biomedical 
applications." Ed.; Elsevier: 1-55. 
 
47 
 
                                                                             
 
 
 
 
 
